DocMorris' shares fell 3.2% to 9.32 Swiss francs in early trading on Wednesday, erasing gains despite a strong first half of 2026 performance and upgraded annual guidance. Η online φαρμακευτική εταιρεία ανέφερε αύξηση 38% στις πωλήσεις φαρμακευτικών προϊόντων (Rx) και αύξηση 71% στα έσοδα από ψηφιακές υπηρεσίες, ωστόσο η αντίδραση της αγοράς παραμένει αρνητική.
Zurich Cantonal Bank (ZKB) assigned a 'Hold' rating on DocMorris, citing balanced growth and cost efficiency as critical factors. Bank noted that planned AI-driven workforce reductions, targeting 7% of full-time roles, could mitigate operational pressures. However, the company faces structural challenges, including a 2027 refinancing requirement and negative free cash flow and operating results.
DocMorris syr til å reducere disse risikoene ved å oppnå positiv frie kontantstrømmer og styrke eierkapitalen gjennom en pågående 50 millioner schweizeriske frank konvertible obligasjon. ZKBs forventninger stemmer overens med en konservativ markeds- konsensus: fem analytikere har «Buy»- anbefaling, fire har «Hold» anbefaling og ingen anbefaler salg. Den gjennomsnittlige prismålet ligger på 11,54 schweizeriske francs, noe som innebærer en oppsiktsvekkende oppgangs- potensial på 20%.
The decline in DocMorris’ shares reflects two key factors. Firstly, the ‘sell the news’ phenomenon, as the company’s mid-July trading update had already priced in strong prescription growth. Secondly, competitive pressure from Redcare, whose German prescription revenue surged by 58% – outpacing DocMorris’ 38% gain. Investors now face the risk of further market share erosion, contributing to the negative sentiment.
ZKB’s revised ratings – improved from four “Buy,” four “Hold,” and one “Sell” six months ago – indicate growing confidence in the stock’s long-term prospects, despite near-term headwinds.
